Biomarker ID | 1821 |
PMID | 30610587 |
Year | 2018 |
Biomarker | AMBP; (cDNA FLJ50830, highly similar to AMBP); (unnamed protein product); (Isoform 2 of Calmodulin-regulated spectrin-associated protein 1-like 1 (CAMSAP1L1); cDNA FLJ51445, highlysimilar to AMBP protein; Ribosomal RNA upstream binding transcription factor (Fragment, UBTF); Basementmembrane-specific heparan sulfate proteoglycan coreprotein (HSPG2); Ferritin heavy chain (FTH1); Transthyretin; 13 kDa protein; Unknown (protein for IMAGE:3934797); Putative beta-actin-like protein 3 F7 Factor VII active sitemutant immunoconjugate; C11orf54 Aminoacylase-1 (ACY1); Ferritin Light chain (FTL) Coactosin-like protein (COTL1); |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Urine |
Subjects | Humans |
Regulation | Methylated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs Controls and Benign Prostatic Hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 3 patients from each group: PCa, BPH; Controls were selected for analysis |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | MALDI-TOF-MS |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |